See more : Zogenix, Inc. (ZGNX) Income Statement Analysis – Financial Results
Complete financial analysis of RxSight, Inc. (RXST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RxSight, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Norris Medicines Limited (NORRIS.BO) Income Statement Analysis – Financial Results
- Thermax Limited (THERMAX.BO) Income Statement Analysis – Financial Results
- Imperial Hotel, Ltd. (9708.T) Income Statement Analysis – Financial Results
- Rion Co., Ltd. (6823.T) Income Statement Analysis – Financial Results
- WESCO International, Inc. (WCC-PA) Income Statement Analysis – Financial Results
RxSight, Inc. (RXST)
About RxSight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 89.08M | 49.01M | 22.59M | 14.68M | 2.24M |
| Cost of Revenue | 35.31M | 27.68M | 18.08M | 12.97M | 4.06M |
| Gross Profit | 53.77M | 21.33M | 4.52M | 1.71M | -1.82M |
| Gross Profit Ratio | 60.36% | 43.52% | 19.99% | 11.62% | -81.17% |
| Research & Development | 29.05M | 25.98M | 24.50M | 21.93M | 29.57M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.80M | 58.67M | 32.81M | 15.18M | 15.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.85M | 84.65M | 57.30M | 37.11M | 44.77M |
| Cost & Expenses | 139.16M | 112.32M | 75.38M | 50.08M | 48.83M |
| Interest Income | 6.57M | 1.52M | 54.00K | 543.00K | 2.31M |
| Interest Expense | 3.31M | 4.95M | 3.68M | 510.00K | 26.00K |
| Depreciation & Amortization | 4.24M | 4.02M | 3.99M | 4.01M | 3.93M |
| EBITDA | -41.04M | -57.78M | -41.01M | 32.15M | 130.20M |
| EBITDA Ratio | -46.07% | -126.11% | -233.40% | -210.18% | -1,800.71% |
| Operating Income | -50.09M | -63.32M | -52.79M | -35.41M | -46.07M |
| Operating Income Ratio | -56.23% | -129.21% | -233.64% | -241.21% | -2,055.78% |
| Total Other Income/Expenses | 1.50M | -3.43M | 4.11M | 63.04M | 172.31M |
| Income Before Tax | -48.59M | -66.75M | -48.68M | 27.63M | 126.24M |
| Income Before Tax Ratio | -54.55% | -136.20% | -215.46% | 188.25% | 5,633.38% |
| Income Tax Expense | 20.00K | 9.00K | 8.00K | 57.00K | 24.00K |
| Net Income | -48.61M | -66.76M | -48.69M | 27.58M | 126.22M |
| Net Income Ratio | -54.57% | -136.22% | -215.50% | 187.87% | 5,632.31% |
| EPS | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| EPS Diluted | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| Weighted Avg Shares Out | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
| Weighted Avg Shares Out (Dil) | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
Source: https://incomestatements.info
Category: Stock Reports